ArticleDrugs - real world outcomes2026
The Effectiveness of the Safety Communication for Concurrent Benzodiazepine-Opioid Therapy: A Retrospective Real-World Analysis.
Article in Drugs - real world outcomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn 2018, Saudi Food and Drug Authority (SFDA) issued a safety communication concerning the potential risk of respiratory depression related to concurrent use of benzodiazepines and opioids. This study aims to evaluate the impact of this safety communication on clinical practice by examining trends in prescribing both medications concurrently pre- and post-safety communication date.
methodsA multicenter retrospective cohort study utilizing data from the Real-world Evidence Research Network comprised adult (≥ 18 years old) users of benzodiazepines and opioids from 2016 throughout 2020. This study employed an interrupted time series analysis using an Autoregressive Integrated Moving Average (ARIMA) model to examine changes in concurrent benzodiazepine and opioid use in Saudi Arabia (SA) before and after the safety communication date. Sensitivity analyses were conducted to assess the reliability of the findings.
resultsA total of 43,906 episodes of concurrent use of benzodiazepines and opioids were identified for 32,035 patients. Comparing concurrent use of benzodiazepines and opioids pre- and post-safety communication, we observed a slight decrease, from 22.5% (22,846 of 101,538 episodes) to 20.4% (21,096 of 103,409 episodes). The result from our selected model, ARIMA, revealed that the estimated step change was 9.3 in prescriptions (95% CI - 154.5 to 173.2) while the estimated change in slope was - 1.7 prescriptions per month (95% CI - 29.4 to 26.1).
conclusionsIn this study, we observed no significant changes in frequencies and trends in concurrent prescriptions of benzodiazepines and opioids before and after the safety communication. This highlights the need for continuous assessment of risk minimization strategies in achieving the targeted outcome.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.